a Background and objective Inosine 5 0 -monophosphate dehydrogenase 2 is required for purine synthesis in activated lymphocytes. Variants in the IMPDH2 gene may account for the large inter-individual variability in baseline enzyme activity, immunosuppressive efficacy and side effects in transplant recipients receiving mycophenolic acid. Therefore, the objective of this study was to identify and functionally characterize IMPDH2 variants.
A novel variant L263F in human inosine 5 0 -monophosphate dehydrogenase 2 is required for purine synthesis in activated lymphocytes. Variants in the IMPDH2 gene may account for the large inter-individual variability in baseline enzyme activity, immunosuppressive efficacy and side effects in transplant recipients receiving mycophenolic acid. Therefore, the objective of this study was to identify and functionally characterize IMPDH2 variants.
Methods DNA samples from 152 solid organ transplant patients were screened at exons and exon/intron junctions of the IMPDH2 genes by PCR amplification followed by bidirectional direct DNA sequencing. Genetic variant was constructed by site-directed mutagenesis and transformed to an inosine 5 0 -monophosphate dehydrogenase-deficient strain of Escherichia coli h712. Proteins were purified to homogeneity and the enzymatic activity was measured by reduced nicotinamide adenine dinucleotide production.
Results Nine genetic variants were identified in the IMPDH2 gene, with frequencies of the rarer alleles ranging from 0.5 to 10.2%. A novel nonsynonymous variant L263F was identified, and the kinetic assay demonstrated that the inosine 5 0 -monophosphate dehydrogenase activity of L263F variant was decreased to 10% of the wild-type. The K i for mycophenolic acid inhibition of the L263F variant was comparable with the wild-type, and the variant K m for inosine 5 0 -monophosphate and nicotinamide adenine dinucleotide did not change significantly.
Conclusions IMPDH2 has low genetic diversity, but the nonsynonymous variant L263F has a significant impact on inosine 5
0 -monophosphate dehydrogenase activity. This novel functional variant may be one of the factors contributing to the inter-individual difference of baseline inosine 5
0 -monophosphate dehydrogenase activity as well as drug efficacy and adverse events in transplant patients. 
Introduction

Inosine 5
0 -monophosphate dehydrogenase (IMPDH) (EC 1.1.1.205) is the target of mycophenolic acid (MPA), the active metabolite of the prodrug mycophenolate mofetil (MMF), which is widely used clinically to prevent allograft rejection in solid organ transplantation [1] . MPA is also used as an immunomodulator in diseases such as AIDS, lupus nephritis, myasthenia gravis and immune thrombocytopenic purpura [2] [3] [4] [5] [6] . Unlike other cell types, which can use the salvage pathway for purine synthesis, lymphocytes are exclusively dependent upon the de-novo pathway catalyzed by IMPDH for the generation of guanosine nucleotide [7, 8] . Drugs active against purine synthesis also have broad applications in oncology, and new agents such as nelarabine [9] continue to advance treatment of T-cell-related diseases.
MPA can uncompetitively, selectively and reversibly inhibit this pathway and therefore inhibit cell proliferation. IMPDH has two isoforms, namely IMPDH type 1 and type 2, and the genes that encode these proteins are located on two different chromosomes [10] . IMPDH1 is constitutively expressed in all tissues, whereas IMPDH2 is required for purine synthesis in activated lymphocytes [11, 12] . Although MPA is demonstrated to inhibit the activities of both IMPDH1 and IMPDH2 isoforms in vitro, IMPDH2 is 4.8 times more sensitive to MPA inhibition than IMPDH1 [13] .
Owing to the difficulty in maintaining the balance between rejection and over-immunosuppression, pharmacokinetic and pharmacodynamic monitoring of MMF has been recommended to optimize drug dosage and administration schedule. Previous studies, however, have not provided a scientific basis for the accurate prediction of MPA's efficacy or side effects [14] . Moreover, large inter-patient and intra-patient variability has been observed in both MPA concentrations and IMPDH activity, and no correlation was found between the two parameters [15] . In some patients with rejection, no inhibition of IMPDH activity was observed despite seemingly adequate MPA concentrations [16] . Considering the significant inter-patient and intra-patient variability of the effects of a given concentration of MPA, the therapeutic range for the desired pharmacologic effect without adverse effects in most patients is difficult to discern [17] .
The considerable variability of baseline IMPDH activity and MPA response may logically be under the control of genetic variation within the IMPDH genes or in gene expression. Although several mutations in the IMPDHbinding site that confer variable degrees of resistance to MPA were found in parasite Tritrichomonas foetus and varying drug-sensitive forms of this enzyme were detected in Saccharomyces cerevisiae, few studies have been reported on IMPDH gene variants in humans [18] [19] [20] . Five different variants of the IMPDH1 gene have been identified in eight autosomal-dominant retinitis pigmentosa families, but their functional significance remains to be defined [21] [22] [23] . One IMPDH2 SNP was recently identified in an abstract as having an association with biopsy-proven rejection in renal transplant patients [24] .
Analysis of genetic variants could provide explanation for the variability of IMPDH activity and MMF response in transplant patients. Owing to its important function in lymphocytes, IMPDH2 was the focus of our initial work to establish genotype-phenotype relationships for genetics variants. The objective of this study was to identify novel IMPDH2 variants, to establish the relationship of this variant to in-vitro activity, and to look for possible clinical correlates for altered IMPDH activity.
Methods
Patient population
A total of 30 DNA samples from liver transplant patients at the University of Southern California, and 30 lung transplant patient as well as 92 heart transplant patient DNA samples from the University of Pittsburgh were included in this study. The protocol was approved by the institutional review boards of the University of Southern California and the University of Pittsburgh, and all patients or guardians provided informed written consent to undergo genotyping. Anticoagulated venous blood was obtained from each patient, and DNA was extracted from whole blood using a commercially available DNA extraction procedure (Qiagen, Valencia, California, USA).
Genotyping
IMPDH2 was PCR-amplified and followed by bidirectional direct DNA sequencing [25] . PCR was carried out in a total volume of 50 ml using 50 ng of genomic DNA, 5 pmol of each forward and reverse primer (Sigma, St Louis, Missouri, USA), 0.2 mmol/l deoxyribonucleotide triphosphate (Promega, Madison Wisconsin, USA), 1 Â PCR buffer and 1.5 units of thermostable Taq DNA polymerase and Tgo DNA polymerase with proofreading activity and high fidelity (Expand 20 kb PLUS PCR system, Roche Applied Science, Penzberg, Germany). The primers used are described in Table 1 . The PCR process included initial denaturation at 921C for 2 min and 10 cycles of denaturation at 921C for 10 s, annealing at 571C for 30 s and synthesis at 681C for 7 min followed by additional 25 cycles of denaturation at 921C for 10 s, annealing at 571C for 30 s and synthesis at 681C for 7 min with the time extended by 10 s for each successive cycle. The final elongation was carried out for 5 min at 721C. Amplified PCR products were purified by using Qiagen PCR purification kit (Qiagen), and sequenced by conventional means using the BigDye Teminator Cycle Sequencing Ready Reaction Kit on ABI 377 XL Sequencer (Applied Biosystems, Foster City, California, USA). SNPs were identified by transferring the chromatograms to sequence assembly software Sequencher 4.1.4 (Gene Codes, Ann Arbor, Michigan, USA). Each base call was compared with the consensus sequence, and the SNPs were confirmed by visual inspection of the chromatograms.
Plasmids and site-directed mutagenesis
The plasmid pHIA5 carrying wild-type human IMPDH2 was kindly provided by Dr Liz Hedstrom (Department of Biochemistry, Brandeis University) [26] . Nonsynonymous variant was made with QuickChange site-directed mutagenesis kit (Strategene, La Jolla, California, USA) using pHIA5 construct as a template. Two complementary primers were designed for the L263F variant as described in Table 1 . PCR cycle conditions were as follows: 951C for 1 min followed by 18 cycles of 951C for Table 1 Sequences of primers used for amplification and sequencing of IMPDH2 and for site-directed mutagenesis 50 s, 601C for 50 s and 681C for 6 min. The final elongation was carried out for 7 min at 681C. After digesting the parental DNA template with DpnI at 371C for 1 h, the PCR product was transformed into DH10B bacteria, and plasmids containing the variant IMPDH2 inserts were isolated. The variant IMPDH2 cDNA was fully sequenced to verify that only the desired mutation had been introduced.
Expression and purification of the inosine 5 0 -monophosphate dehydrogenase 2 wild-type and L263F variant
The plasmids containing the IMPDH gene were transformed and expressed in H712 cells, an IMPDHdeficient strain of Escherichia coli. H712 cells carrying pHIA5 were grown overnight in 3 l of Luria-Bertani medium containing 1 mmol/l isopropyl b-D-1-thiogalactopyranaside (IPTG) and 100 mg/ml ampicillin. The cells were harvested by centrifugation and resuspended in Buffer A with 100 mmol/l Tris (pH 7.5), 1 mmol/l dithiothreitol and 10% glycerol. The cells were frozen, thawed and then disrupted by sonication with 2 Â 20 pulses at power setting 5 (Misonix 3000 with microtip probe Misoniz, Inc., Farmingdale, New York, USA). Cell debris was removed by centrifugation at 18 000g for 30 min. The crude lysate was applied to a Cibacron Blue Sepharose column (Sigma, St. Louis, Missouri, USA) preequilibrated in Buffer A. IMPDH was eluted in a linear gradient of 0-1 mol/l KCl. The IMPDH containing fractions were pooled, diluted in Buffer A and applied to an inosine 5 0 -monophosphate (IMP) affinity column prepared by coupling IMP to epoxy-activated Sepharose as described [27] . IMPDH was eluted in 80 ml of Buffer A containing 2 mmol/l IMP. The fractions were collected and judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and proteins were pooled and concentrated using Amicon Centriprep filters (Millipore, Billerica, Massachusetts, USA). IMP was removed by dialysis against 4 l of buffer A overnight at 41C. Protein purity was evaluated by Bio-Safe Coomassie Blue staining (Bio-Rad, Hercules, California, USA). Protein concentration was determined by microBCA protein assay kit (Pierce, Rockford, Illinois, USA) [26] .
Enzyme kinetic assays IMPDH2 activity was assayed after protein purification as previously described [26] . IMP, NAD + and NADH were purchased from Sigma. For the kinetic analysis, assays were performed at 371C in 200 ml buffer of 100 mmol/l Tris HCl, 10 mmol/l KCl, 3 mmol/l ethylenediaminetetraacetic acid, 2 mmol/l dithiothreitol, pH 8.0. The reaction was started by the addition of enzyme (15-30 nmol/l), and the rates were obtained by monitoring NADH formation at 340 nm for 30 min in a temperature-controlled 96-well microtiter Table 2 Genetic variants of IMPDH2 in transplant patients detected by bidirectional DNA sequencing 
Genetic variation in
plate reader (Bio-Rad). The extinction coefficient of 6.2 mmol/l/cm at 340 nm was used for NADH. Michaelis constants for IMP and NAD + were calculated from substrate titration data at saturating concentrations of the other substrate using the Michaelis-Menten equation (equation 1). The inhibition of IMPDH2 by MPA was assayed at varying concentrations of NAD and MPA in the presence of saturating IMP (400 mmol/l). The inhibition constants of MPA were determined by fitting the data to the equation for standard uncompetitive inhibition (equation 2) using the program Prism version 3.02 (GraphPad, San Diego, California, USA).
where v is the initial velocity, k cat is the turnover number, E is IMPDH enzyme concentration, K m is the Michaelis constant, S is the substrate concentration, v m is the maximum velocity, K i is the inhibition constant and I is the inhibitor concentration.
Western blot
Wild-type or L263F variant of IMPDH2 proteins were incubated with or without 400 mmol/l of IMP and NAD + in a final volume of 200 ml at 371C for 8 h. MPA was also added in a final concentration of 0 or 10 mmol/l. Samples were size fractionated on a 7.5% polyacrylamide gel containing 0.1% SDS (w/v) and transferred onto Immobilon polyvinylidene difluoride membranes (Millipore, Billerica, Massachusetts, USA) using a Transblotter (Bio-Rad). The membrane containing proteins was incubated with the antihIMPDH antibody (Antibody solutions, Mountain View, California, USA) at 1 : 200 dilutions (5 ug/ml) in Trisbuffered saline, supplemented with 0.1% Tween 20 and 5% milk. The proteins were visualized using the ECL kit (Amersham Biosciences, Piscataway, New Jersey, USA), and the band signal density was analyzed by Discovery Series Quantity One 1-D Analysis software (Bio-Rad).
Results
Genetic variants in inosine 5
0 -monophosphate dehydrogenase 2
To examine IMPDH2 genetic variation, we directly sequenced the 300 bp upstream of the proximal promoter region, 14 exons and the intron-exon boundary regions from 152 genomic DNA samples from these transplant patients. Nine genetic variants including eight novel SNPs were identified and confirmed by bidirectional sequencing (Table 2) . Two variants are located in exons and seven are in the intronic regions. One novel variant 787C > T was identified in exon 7 of IMPDH2, leading to an amino acid change from leucine to phenylalanine at amino acid residue 263 (Fig. 1) . This residue is located within the a-helix of the a/b barrel core domain of IMPDH2 protein which contains the entire machinery for enzyme catalytic activity (Fig. 2a) .
Enzyme activities of inosine 5
0 -monophosphate dehydrogenase 2 wild-type and L263F variant An alignment of IMPDH amino acid sequences from different species demonstrates that the leucine residue 263 is highly conserved through a diversity of organisms, indicating its potential functional importance (Fig. 2b) . Site-directed mutagenesis was used to generate the variant. Compared with the wild-type, L263F variant expressed less than 50% of the protein level from the IMPDH-deficient Escherichia coli. The purified protein had > 95% homogeneity as determined by densitometry of SDS-PAGE gels stained with Coomassie blue (Fig. 3a) . Enzyme kinetic analysis demonstrated that the L263F variant had a 10-fold decrease in k cat value relative to the wild-type (Table 3 ; Fig. 3b and c) . The K m value for IMP and NAD + did not change significantly, although there was a slight increase for NAD + ( Table 3) . The K i for MPA inhibition of L263F variant was also comparable with wild-type (Table 3) . Western-blot analysis was performed after incubating purified recombinant human IMPDH2 with IMP and NAD + in the absence or presence of MPA. Our results demonstrated a significant gel mobility shift of the proteins from the 56 kDa to more than 220 kDa upon MPA treatment at 371C for 8 h (Fig. 4) . The shift was evident in both the wild-type protein and the L263F variant.
Discussion
Drug dosing and monitoring for an agent such as MPA is critical for obtaining an antiproliferative response without significant drug toxicity. Drug levels alone do not predict freedom from rejection or long-term graft function in transplant patients [28, 29] . The measurement of IMPDH activity in peripheral blood has been proposed as a measure of MPA effect, and high pretransplant IMPDH activity with MMF dose reductions have been associated with the development of acute rejection [30] . Significant inter-individual variability in IMPDH activity can, however, be observed in the isolated lymphocytes of both healthy participants and dialysis patients [15] . IMPDH2 mRNA from peripheral blood has even been explored as a biomarker for MPA activity [31] . In the end, side effects such as leukopenia or failure to exert an antirejection effect by MPA in patients could possibly be explained by the genetic variance in IMPDH genes leading to functional differences. This report is the first study of IMPDH2 genetic variants in the transplant patients. We found nine genetic variants separately located in the introns and exons with allele frequencies Genetic variation in IMPDH2 changes activity Wang et al. 287
ranging from 0.5 to 10.2%. The nonsynonymous variant 787C > T located in exon 7 leads to amino acid substitution from Leu to Phe at residue 263.
A subsequent report has recently appeared in abstract form, and reports on a previously unidentified IMPDH2 single nucleotide polymorphism (SNP) in renal transplant patients [24] . The IMPDH2 3757 C allele, presumably in intron 9, reportedly increased the odds of developing biopsy-proven acute rejection in renal transplant patients by three-fold. Other gene polymorphisms may affect the disposition of MPA and its glucuronide metabolite, and include the multidrug resistance-associated protein 2 transporter [32, 33] and the uridine diphosphate glucuronosyl transferases [34] .
Two prominent domains have been identified in the X-ray crystal structure of IMPDH [35, 36] . Residue 263 is highly conserved in various organisms, and is located in the a-helix of the IMPDH core domain encompassing amino acids 1-108 and 244-514 (Fig. 2a) . These segments contain the entire enzymatic machinery necessary for IMPDH catalytic function. Kinetic analysis demonstrated that L263F mutation produced a dramatic drop in IMPDH enzyme activity in vitro, indicating that a leucine at residue 263 is important for normal enzyme function (Table 3 ; Fig. 3b, c) . Therefore, lymphocytes carrying this variant may have decreased baseline IMPDH activity in vivo. The bulky phenylalanine, unlike leucine, inserts an aromatic ring within the sequence, which could lead to secondary structure changes. Alignment results demonstrated that this amino acid is highly conserved in various organisms (Fig. 2b) . No homozygous TT genotype was found in our sample population, possibly because this mutation could be incompatible with life although no studies to date have confirmed this.
The K i value for MPA inhibition showed that wild-type and L263 variant IMPDH2 had comparable sensitivity to MPA (Table 3 ). Previous studies indicated that gel mobility shift could provide a surrogate marker for IMPDH inhibition in clinical studies [20, 37] . Therefore, we performed Western-blot analysis for human IMPDH2 incubating with IMP and NAD + in the absence or presence of MPA (Fig. 4) . The gel mobility shift demonstrated that MPA could lead to self-aggregation of both wild-type and L263F variant, possibly through protein conformational changes [37] . These data, together with the MPA inhibition assay, indicate that the L263F variant was inhibited by MPA in a similar manner as the wild-type IMPDH2.
To determine whether the IMPDH2 L263F variant is associated with any clinical relevance in MPA-treated transplant patients, we reviewed the clinical information in 30 liver transplant patients. Two patients were found to be heterozygous CT at the L263F site on IMPDH2. Both of these two patients had received living donor liver transplants, and similar immunosuppressive regimens consisting of MMF, tacrolimus and low-dose corticosteroids. At the time of their lowest white blood cell count (WBC) in the first postoperative year, both patients were receiving 0.5 g of MMF daily, or approximately 10 mg/kg/ day. Dosing in the other patients ranged from 6 to 44 mg/ kg/day of MMF given orally. Neither patient was receiving antiviral therapy or acute antirejection therapy with high dose corticosteroids or antibody therapy at the time of their leukocyte nadir. Patient 1 had mild leukopenia with a WBC of 3700/ml, 1.7 months after liver transplantation. Patient 2 had moderate leukopenia with a WBC of 2500/ml, 2 and 1.5 months after transplantation. In Patient 2, the MMF was discontinued owing to leukopenia, and rechallenge with MMF after a second transplant also produced leukopenia necessitating drug discontinuation. Further investigation of the IMPDH genotype-phenotype relationship may provide useful information for the clinical management of IMPDHtargeted drugs.
In conclusion, we identified a novel L263F variant in the IMPDH2 gene. To our knowledge, this is the first reported variant associated with decreased enzyme activity. Future clinical studies are warranted to determine whether this variant and others are associated with MPA efficacy and toxicity, and then to develop and test prospective treatment algorithms that will improve the use of the drug in organ transplant patients.
